Upgrade to SI Premium - Free Trial

BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $188 at Goldman Sachs, After FDA CRL

August 19, 2020 11:07 AM
Goldman Sachs analyst Salveen Richter ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst PT Change

Next Articles